The relationship between high Lp(a) levels and proprotein convertase subtilisin/kexin type 9 (PCSK9) was not investigated until 2018, when Sun et al. reported their data obtained from patients with heterozygous FH; it has been shown only recently that Lp(a) levels can be decreased with the use of PCSK9 inhibitors (Sun et al., 2018). Here, PCSK9 is linked to familial hyperaldosteronism.